HIGHLIGHTS
- who: Savvas Papageorgiou et al. from the Department of Molecular and Cell Biology, University of Leicester, Lancaster Road, Leicester , RH, UK have published the paper: Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer, in the Journal: Cancers 2022, 14, 3452. of /2022/
- what: The aim of this review is to address this gap by providing a summary of recent advances in the understanding of the mechanisms underpinning EML4-ALK-driven NSCLC that might reveal alternative treatment options to ALK TKI monotherapy. This study proposes the use of CDK inhibitors as . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.